Salmonella enterica serovar Abortusovis (S. Abortusovis) infection is one of the most important causes of infectious late-term abortion as well as birth of weak lambs in sheep in many countries throughout the world. Implementation of protocols based on the application of effective vaccines is one of the most effective approaches for controlling this disease, but variable efficacy has been reported, possibly related to factors associated with the host, the vaccine, the parameters used for determining efficacy and the challenge protocols. In this context, a new commercial inactivated vaccine (INMEVA; Laboratorios Hipra S.A., Spain) was evaluated in 20 control and 17 vaccinated gestating ewes, subcutaneously challenged at 90 days of gestation with 5 × 10⁶ colony-forming units (cfu) of a wild strain of S. Abortusovis. Incidence of reproductive failures, bacterial vaginal excretion (by real time PCR), and lamb survival were evaluated as indicators of the vaccine's level of protection. Moreover, humoral response (by ELISA test in serum samples) was studied. Vaccination was showed to be safe under the study conditions. Vaccine efficacy was demonstrated in two different ways: i) it significantly decreased the percentage of abortions [29.4% (5/17) in the vaccinated group compared to the control group (65%; 13/20)] and ii) there was a significant reduction of the overall vaginal excretion in the sampling period (3.05 log cfu/mL ± 0.84 in the vaccinated group vs. 5.68 ± 0.67 in the control group).

Given these results, the vaccine evaluated can be considered as an effective alternative for controlling S. Abortusovis infection in ovine flocks.

肠炎沙门氏菌沙门氏菌（S. Abortusovis）感染是世界上许多国家绵羊后期感染性流产以及弱羔羊出生的最重要原因之一。基于有效疫苗的应用方案的实施是控制该疾病的最有效方法之一，但已报道了可变的功效，可能与宿主，疫苗，用于确定功效的参数和挑战相关的因素有关协议。在这种情况下，在20个对照组和17个接种母羊中评估了一种新的商业灭活疫苗（INMEVA； Laboratorios Hipra SA，西班牙），在妊娠90天时皮下攻击5×10 ⁶S.野生菌株的菌落形成单位（cfu）。Abortusovis。生殖衰竭，细菌阴道排泄（通过实时PCR）和羔羊存活的发生率被评估为疫苗保护水平的指标。此外，还研究了体液反应（通过血清样品中的ELISA测试）。在研究条件下，接种疫苗是安全的。疫苗的有效性通过两种不同的方式进行了证明：i）显着降低了流产的百分比[与对照组（65％; 13/20）相比，接种组的流产百分比为29.4％（5/17）]，并且ii）采样期间总体阴道排泄量显着降低（接种组为3.05 log cfu / mL±0.84，而对照组为5.68±0.67）。

鉴于这些结果，所评估的疫苗可被视为控制S的有效替代品。羊群中的阿波图索病毒感染。